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Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, we have seen shortages of diagnostic reagents, consumables and personal protective equipment \[[@bib1],[@bib2]\]. Initially we inactivated samples with guanidine hydrochloride (GuHCl) before SARS-CoV-2 testing \[[@bib2],[@bib3]\]. Following implementation of cobas SARS-CoV-2 testing (Roche, Basel, Switzerland), we encountered shortages of GuHCl and personal protective equipment. To overcome these issues, we investigated a number of rapid heat treatment steps before cobas testing. Temperatures and durations investigated were based on reports demonstrating the effects of temperature on the viability of SARS-CoV-2 (70°C for 5 minutes) \[[@bib4]\] and other coronaviruses \[[@bib5], [@bib6], [@bib7]\].

To test the effects of thermal treatment on cobas assay performance, we tenfold serially diluted cobas-positive clinical samples collected in Copan UTMRT media (Brescia, Italy) from different patients (*n* = 8) using cobas-negative nasopharyngeal matrix and thermally treated incrementally at 60°C, 65°C and 75°C (UTM internal temperature) for a total time of 15 minutes, 30 minutes and 60 minutes at each temperature point. Aliquots were prepared in cobas omni secondary tubes (ref. 06438776001) and were thermally treated in a Dri-Bath. An aliquot of each dilution remained untreated (room-temperature control), and cobas testing was performed in parallel for all samples (*n* = 34). We also prospectively tested 40 consecutive patient samples comparing 75°C for 15 minutes to room temperature ([Table 1](#tbl1){ref-type="table"} and [Supplementary Material](#appsec1){ref-type="sec"}).Table 1Summary of cobas SARS-CoV-2 results in 74 samplesTable 1Result outcomeNo. of samplescobas SARS-CoV-2 result for:Heat treatmentRoom-temperature control122DetectedDetected23DetectedNegative33Presumptive positiveNegative41Presumptive positivePresumptive positive545NegativeNegative[^1][^2]

All samples were heated immediately before extraction and were loaded without delay (\<5 minutes). We recorded the cycle threshold (*C* ~*t*~) for ORF1a, E-gene and internal control. All *C* ~*t*~ values are shown in the Supplementary Material, and the qualitative results are shown in [Table 1](#tbl1){ref-type="table"}. Positive *C* ~*t*~ values in both ORF1a and E-gene for thermally treated and room-temperature control were compared by the two-tailed paired *t* test (p \< 0.05). The same statistical approach was applied for all internal control *C* ~*t*~ values. All *C* ~*t*~ values were normally distributed (D\'Agostino-Pearson test). For thermal treated compared to room-temperature control, we found no significant difference in *C* ~*t*~ values for ORF1a (22 samples compared, mean difference +0.13 ± 0.89 SD, p 0.502). However, a significant difference was observed for E-gene (21 samples compared, mean difference +0.55 ± 1.15 SD, p 0.040) and internal control (all 74 samples compared, −0.27 ± 0.40 SD, p 0.00001). In summary, the mean ORF1a and E-gene *C* ~*t*~ values were 0.13 and 0.55 *C* ~*t*~ higher for heat treatment than control respectively.

Higher *C* ~*t*~ values for thermally treated samples may suggest a reduction in detectable virus RNA. A recent study using a commercial qualitative method (BioGerm Medical Biotechnology, Shanghai, China) and quantitative digital PCR (TargetingOne, Beijing, China) demonstrated a drop in SARS-CoV-2 copy number by 50% to 66% after heating at 80°C for 20 minutes \[[@bib8]\]. However, internal control test performance was not evaluated (or not included as part of the assay), and correlation with other commercial *in vitro* diagnostic assays or cobas is not known. Despite marginally higher cobas *C* ~*t*~ values for thermally treated samples in our study, conflicting findings were observed for the qualitative detection of SARS-CoV-2, specifically detection of ORF1a and E-gene targets at the limit of detection ([Table 1](#tbl1){ref-type="table"}). Although we observed *C* ~*t*~ shifts in the cobas E-gene target, the cobas assay is dual target, and therefore the delay in one target may not be critical to the qualitative detection of SARS-CoV-2. Of 34 dilutions prepared, SARS-CoV-2 was detected in three thermally treated samples (ORF1a ± E-gene) and three were presumptively positive for SARS-CoV-2 (E-gene only), all of which were negative for the room-temperature control.

On the basis of these results, heat treatment may improve the qualitative detection of SARS-CoV-2. To confirm our qualitative findings, many replicates at the lower limit of detection combined with probit analysis are required. As a result of safety concerns and suboptimal recovery of SARS-CoV-2 from culture, our laboratory did not confirm the inactivation efficacy of thermal treatment. However, using standard biosafety level 2 (BSL2) laboratory safety procedures, we continue to use the highest temperature assessed with a time that suits the work flow (75°C for 15 minutes), thereby exceeding a previously published temperature and duration of 70°C for 5 minutes for complete SARS-CoV-2 inactivation in virus transport medium \[[@bib4]\].

We acknowledge that thermal inactivation of SARS-CoV-2 may not be 100% efficient \[[@bib4], [@bib5], [@bib6], [@bib7]\]. However, we consider the risk to staff in a well-equipped BSL2 laboratory is greatly reduced with thermal pretreatment. Moreover, thermal treatment negates the need for GuHCl and enables the redirection of personal protective equipment to frontline personnel.

Transparency declaration {#sec1}
========================

Funding was provided by PathWest. All authors report no conflicts of interest relevant to this article.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the Supplementary data to this article:Multimedia component 1Multimedia component 1

The authors are grateful to Adrian Bautista (Acting Chief Executive of PathWest at the commencement of COVID-19 testing) for provisioning the cobas kits.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cmi.2020.07.042>.

[^1]: Detected indicates ORF1a positive, E-gene positive; presumptive positive, ORF1a negative, E-gene positive.

[^2]: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
